Loading…

Barrett’s Esophagus and Esophageal Adenocarcinoma Are Common After Treatment for Achalasia

Background Achalasia is characterized by esophageal aperistalsis and impaired relaxation of the lower esophageal sphincter (LES). This contrasts with an insufficient LES, predisposing to gastro-esophageal reflux and Barrett’s esophagus. The co-incidence of achalasia and BE is rare. Pneumatic dilatat...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2013, Vol.58 (1), p.244-252
Main Authors: Leeuwenburgh, I., Scholten, P., Caljé, T. J., Vaessen, R. J., Tilanus, H. W., Hansen, B. E., Kuipers, E. J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c472t-eccd0309c675c4b6613440d82e965fbbb7771cc85fde758e5650422142eb01e3
cites cdi_FETCH-LOGICAL-c472t-eccd0309c675c4b6613440d82e965fbbb7771cc85fde758e5650422142eb01e3
container_end_page 252
container_issue 1
container_start_page 244
container_title Digestive diseases and sciences
container_volume 58
creator Leeuwenburgh, I.
Scholten, P.
Caljé, T. J.
Vaessen, R. J.
Tilanus, H. W.
Hansen, B. E.
Kuipers, E. J.
description Background Achalasia is characterized by esophageal aperistalsis and impaired relaxation of the lower esophageal sphincter (LES). This contrasts with an insufficient LES, predisposing to gastro-esophageal reflux and Barrett’s esophagus. The co-incidence of achalasia and BE is rare. Pneumatic dilatation (PD) may lead to gastro-esophageal reflux, Barrett’s esophagus development, and esophageal adenocarcinoma. Aims To determine the incidence of Barrett’s esophagus and esophageal adenocarcinoma in achalasia patients treated with PD. Methods We performed a single-center cohort follow-up study of 331 achalasia patients treated with PD. Mean follow-up was 8.9 years, consisting of regular esophageal manometry, timed barium esophagram, and endoscopy. Results Twenty-eight (8.4 %) patients were diagnosed with Barrett’s esophagus, one at baseline endoscopy. This corresponds with an annual incidence of Barrett’s esophagus of 1.00 % (95 % CI 0.62–1.37). Hiatal herniation was present in 74 patients and 21 developed Barrett’s esophagus compared to seven of 257 patients without a hiatal hernia. Statistical analysis revealed a hazard ratio of 8.04 to develop Barrett’s esophagus if a hiatal hernia was present. Post-treatment LES pressures were lower in patients with Barrett’s esophagus than in those without (13.9 vs. 17.4 mmHg; p  = 0.03). Two (0.6 %) patients developed esophageal adenocarcinoma during follow-up. Conclusions Barrett’s esophagus is incidentally diagnosed in untreated achalasia patients despite high LES pressures, but is more common after successful treatment, especially in the presence of hiatal herniation. Patients treated for achalasia should be considered for GERD treatment and surveillance of development of Barrett’s esophagus, in particular, when they have low LES pressures and a hiatal herniation.
doi_str_mv 10.1007/s10620-012-2157-9
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1942216925</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712946901</galeid><sourcerecordid>A712946901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c472t-eccd0309c675c4b6613440d82e965fbbb7771cc85fde758e5650422142eb01e3</originalsourceid><addsrcrecordid>eNqFkc1u1TAQhS1ERS-FB2CDLLFhk-JxYjtehqvyI1Vic5eVLMeZ3KZK7IudLNjxGrweT4LDbcuPQJUX47G_czSjQ8gLYOfAmHqTgEnOCga84CBUoR-RTa5lwYWsH5MNA5nvAPKUPE3phjGmFcgn5JSXoDRUfEOu3toYcZ6_f_2W6EUKh2u7XxK1vrvr0I606dAHZ6MbfJgsbSLSbZim4GnTzxjpLqKdJ_Qz7UOkjbu2o02DfUZOejsmfH5bz8ju3cVu-6G4_PT-47a5LFyl-Fygcx0rmXZSCVe1UkJZVayrOWop-rZtlVLgXC36DpWoUUjBKs7z_NgywPKMvD7aHmL4vGCazTQkh-NoPYYlGdArLTUXD6O85nWpJYeMvvoLvQlL9HmPnxQvWaXlL2pvRzSD78McrVtNTaOA60pqtnqd_4PKp8NpcMFjP-T3PwRwFLgYUorYm0McJhu_GGBmzd4cszc5e7Nmb3TWvLwdeGkn7O4Vd2FngB-BlL_8HuNvG_3X9Qc4braz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1282230496</pqid></control><display><type>article</type><title>Barrett’s Esophagus and Esophageal Adenocarcinoma Are Common After Treatment for Achalasia</title><source>Springer Nature</source><creator>Leeuwenburgh, I. ; Scholten, P. ; Caljé, T. J. ; Vaessen, R. J. ; Tilanus, H. W. ; Hansen, B. E. ; Kuipers, E. J.</creator><creatorcontrib>Leeuwenburgh, I. ; Scholten, P. ; Caljé, T. J. ; Vaessen, R. J. ; Tilanus, H. W. ; Hansen, B. E. ; Kuipers, E. J.</creatorcontrib><description>Background Achalasia is characterized by esophageal aperistalsis and impaired relaxation of the lower esophageal sphincter (LES). This contrasts with an insufficient LES, predisposing to gastro-esophageal reflux and Barrett’s esophagus. The co-incidence of achalasia and BE is rare. Pneumatic dilatation (PD) may lead to gastro-esophageal reflux, Barrett’s esophagus development, and esophageal adenocarcinoma. Aims To determine the incidence of Barrett’s esophagus and esophageal adenocarcinoma in achalasia patients treated with PD. Methods We performed a single-center cohort follow-up study of 331 achalasia patients treated with PD. Mean follow-up was 8.9 years, consisting of regular esophageal manometry, timed barium esophagram, and endoscopy. Results Twenty-eight (8.4 %) patients were diagnosed with Barrett’s esophagus, one at baseline endoscopy. This corresponds with an annual incidence of Barrett’s esophagus of 1.00 % (95 % CI 0.62–1.37). Hiatal herniation was present in 74 patients and 21 developed Barrett’s esophagus compared to seven of 257 patients without a hiatal hernia. Statistical analysis revealed a hazard ratio of 8.04 to develop Barrett’s esophagus if a hiatal hernia was present. Post-treatment LES pressures were lower in patients with Barrett’s esophagus than in those without (13.9 vs. 17.4 mmHg; p  = 0.03). Two (0.6 %) patients developed esophageal adenocarcinoma during follow-up. Conclusions Barrett’s esophagus is incidentally diagnosed in untreated achalasia patients despite high LES pressures, but is more common after successful treatment, especially in the presence of hiatal herniation. Patients treated for achalasia should be considered for GERD treatment and surveillance of development of Barrett’s esophagus, in particular, when they have low LES pressures and a hiatal herniation.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-012-2157-9</identifier><identifier>PMID: 23179142</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adenocarcinoma ; Adenocarcinoma - etiology ; Adult ; Aged ; Aged, 80 and over ; Analysis ; Barium ; Barrett Esophagus - etiology ; Biochemistry ; Development and progression ; Drug therapy ; Esophageal Achalasia - complications ; Esophageal diseases ; Esophageal Neoplasms - etiology ; Female ; Follow-Up Studies ; Gastroenterology ; Gastrointestinal agents ; Health aspects ; Hepatology ; Hernia ; Histamine H2 Antagonists ; Humans ; Male ; Medical research ; Medicine ; Medicine &amp; Public Health ; Medicine, Experimental ; Middle Aged ; Oncology ; Original Article ; Pneumoviridae ; Proton Pump Inhibitors ; Transplant Surgery ; Treatment Outcome</subject><ispartof>Digestive diseases and sciences, 2013, Vol.58 (1), p.244-252</ispartof><rights>Springer Science+Business Media New York 2012</rights><rights>COPYRIGHT 2013 Springer</rights><rights>Springer Science+Business Media, LLC 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c472t-eccd0309c675c4b6613440d82e965fbbb7771cc85fde758e5650422142eb01e3</citedby><cites>FETCH-LOGICAL-c472t-eccd0309c675c4b6613440d82e965fbbb7771cc85fde758e5650422142eb01e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23179142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leeuwenburgh, I.</creatorcontrib><creatorcontrib>Scholten, P.</creatorcontrib><creatorcontrib>Caljé, T. J.</creatorcontrib><creatorcontrib>Vaessen, R. J.</creatorcontrib><creatorcontrib>Tilanus, H. W.</creatorcontrib><creatorcontrib>Hansen, B. E.</creatorcontrib><creatorcontrib>Kuipers, E. J.</creatorcontrib><title>Barrett’s Esophagus and Esophageal Adenocarcinoma Are Common After Treatment for Achalasia</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background Achalasia is characterized by esophageal aperistalsis and impaired relaxation of the lower esophageal sphincter (LES). This contrasts with an insufficient LES, predisposing to gastro-esophageal reflux and Barrett’s esophagus. The co-incidence of achalasia and BE is rare. Pneumatic dilatation (PD) may lead to gastro-esophageal reflux, Barrett’s esophagus development, and esophageal adenocarcinoma. Aims To determine the incidence of Barrett’s esophagus and esophageal adenocarcinoma in achalasia patients treated with PD. Methods We performed a single-center cohort follow-up study of 331 achalasia patients treated with PD. Mean follow-up was 8.9 years, consisting of regular esophageal manometry, timed barium esophagram, and endoscopy. Results Twenty-eight (8.4 %) patients were diagnosed with Barrett’s esophagus, one at baseline endoscopy. This corresponds with an annual incidence of Barrett’s esophagus of 1.00 % (95 % CI 0.62–1.37). Hiatal herniation was present in 74 patients and 21 developed Barrett’s esophagus compared to seven of 257 patients without a hiatal hernia. Statistical analysis revealed a hazard ratio of 8.04 to develop Barrett’s esophagus if a hiatal hernia was present. Post-treatment LES pressures were lower in patients with Barrett’s esophagus than in those without (13.9 vs. 17.4 mmHg; p  = 0.03). Two (0.6 %) patients developed esophageal adenocarcinoma during follow-up. Conclusions Barrett’s esophagus is incidentally diagnosed in untreated achalasia patients despite high LES pressures, but is more common after successful treatment, especially in the presence of hiatal herniation. Patients treated for achalasia should be considered for GERD treatment and surveillance of development of Barrett’s esophagus, in particular, when they have low LES pressures and a hiatal herniation.</description><subject>Adenocarcinoma</subject><subject>Adenocarcinoma - etiology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Barium</subject><subject>Barrett Esophagus - etiology</subject><subject>Biochemistry</subject><subject>Development and progression</subject><subject>Drug therapy</subject><subject>Esophageal Achalasia - complications</subject><subject>Esophageal diseases</subject><subject>Esophageal Neoplasms - etiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology</subject><subject>Gastrointestinal agents</subject><subject>Health aspects</subject><subject>Hepatology</subject><subject>Hernia</subject><subject>Histamine H2 Antagonists</subject><subject>Humans</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pneumoviridae</subject><subject>Proton Pump Inhibitors</subject><subject>Transplant Surgery</subject><subject>Treatment Outcome</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1TAQhS1ERS-FB2CDLLFhk-JxYjtehqvyI1Vic5eVLMeZ3KZK7IudLNjxGrweT4LDbcuPQJUX47G_czSjQ8gLYOfAmHqTgEnOCga84CBUoR-RTa5lwYWsH5MNA5nvAPKUPE3phjGmFcgn5JSXoDRUfEOu3toYcZ6_f_2W6EUKh2u7XxK1vrvr0I606dAHZ6MbfJgsbSLSbZim4GnTzxjpLqKdJ_Qz7UOkjbu2o02DfUZOejsmfH5bz8ju3cVu-6G4_PT-47a5LFyl-Fygcx0rmXZSCVe1UkJZVayrOWop-rZtlVLgXC36DpWoUUjBKs7z_NgywPKMvD7aHmL4vGCazTQkh-NoPYYlGdArLTUXD6O85nWpJYeMvvoLvQlL9HmPnxQvWaXlL2pvRzSD78McrVtNTaOA60pqtnqd_4PKp8NpcMFjP-T3PwRwFLgYUorYm0McJhu_GGBmzd4cszc5e7Nmb3TWvLwdeGkn7O4Vd2FngB-BlL_8HuNvG_3X9Qc4braz</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Leeuwenburgh, I.</creator><creator>Scholten, P.</creator><creator>Caljé, T. J.</creator><creator>Vaessen, R. J.</creator><creator>Tilanus, H. W.</creator><creator>Hansen, B. E.</creator><creator>Kuipers, E. J.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>2013</creationdate><title>Barrett’s Esophagus and Esophageal Adenocarcinoma Are Common After Treatment for Achalasia</title><author>Leeuwenburgh, I. ; Scholten, P. ; Caljé, T. J. ; Vaessen, R. J. ; Tilanus, H. W. ; Hansen, B. E. ; Kuipers, E. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c472t-eccd0309c675c4b6613440d82e965fbbb7771cc85fde758e5650422142eb01e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma</topic><topic>Adenocarcinoma - etiology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Barium</topic><topic>Barrett Esophagus - etiology</topic><topic>Biochemistry</topic><topic>Development and progression</topic><topic>Drug therapy</topic><topic>Esophageal Achalasia - complications</topic><topic>Esophageal diseases</topic><topic>Esophageal Neoplasms - etiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology</topic><topic>Gastrointestinal agents</topic><topic>Health aspects</topic><topic>Hepatology</topic><topic>Hernia</topic><topic>Histamine H2 Antagonists</topic><topic>Humans</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pneumoviridae</topic><topic>Proton Pump Inhibitors</topic><topic>Transplant Surgery</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leeuwenburgh, I.</creatorcontrib><creatorcontrib>Scholten, P.</creatorcontrib><creatorcontrib>Caljé, T. J.</creatorcontrib><creatorcontrib>Vaessen, R. J.</creatorcontrib><creatorcontrib>Tilanus, H. W.</creatorcontrib><creatorcontrib>Hansen, B. E.</creatorcontrib><creatorcontrib>Kuipers, E. J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leeuwenburgh, I.</au><au>Scholten, P.</au><au>Caljé, T. J.</au><au>Vaessen, R. J.</au><au>Tilanus, H. W.</au><au>Hansen, B. E.</au><au>Kuipers, E. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Barrett’s Esophagus and Esophageal Adenocarcinoma Are Common After Treatment for Achalasia</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2013</date><risdate>2013</risdate><volume>58</volume><issue>1</issue><spage>244</spage><epage>252</epage><pages>244-252</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>Background Achalasia is characterized by esophageal aperistalsis and impaired relaxation of the lower esophageal sphincter (LES). This contrasts with an insufficient LES, predisposing to gastro-esophageal reflux and Barrett’s esophagus. The co-incidence of achalasia and BE is rare. Pneumatic dilatation (PD) may lead to gastro-esophageal reflux, Barrett’s esophagus development, and esophageal adenocarcinoma. Aims To determine the incidence of Barrett’s esophagus and esophageal adenocarcinoma in achalasia patients treated with PD. Methods We performed a single-center cohort follow-up study of 331 achalasia patients treated with PD. Mean follow-up was 8.9 years, consisting of regular esophageal manometry, timed barium esophagram, and endoscopy. Results Twenty-eight (8.4 %) patients were diagnosed with Barrett’s esophagus, one at baseline endoscopy. This corresponds with an annual incidence of Barrett’s esophagus of 1.00 % (95 % CI 0.62–1.37). Hiatal herniation was present in 74 patients and 21 developed Barrett’s esophagus compared to seven of 257 patients without a hiatal hernia. Statistical analysis revealed a hazard ratio of 8.04 to develop Barrett’s esophagus if a hiatal hernia was present. Post-treatment LES pressures were lower in patients with Barrett’s esophagus than in those without (13.9 vs. 17.4 mmHg; p  = 0.03). Two (0.6 %) patients developed esophageal adenocarcinoma during follow-up. Conclusions Barrett’s esophagus is incidentally diagnosed in untreated achalasia patients despite high LES pressures, but is more common after successful treatment, especially in the presence of hiatal herniation. Patients treated for achalasia should be considered for GERD treatment and surveillance of development of Barrett’s esophagus, in particular, when they have low LES pressures and a hiatal herniation.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23179142</pmid><doi>10.1007/s10620-012-2157-9</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-2116
ispartof Digestive diseases and sciences, 2013, Vol.58 (1), p.244-252
issn 0163-2116
1573-2568
language eng
recordid cdi_proquest_miscellaneous_1942216925
source Springer Nature
subjects Adenocarcinoma
Adenocarcinoma - etiology
Adult
Aged
Aged, 80 and over
Analysis
Barium
Barrett Esophagus - etiology
Biochemistry
Development and progression
Drug therapy
Esophageal Achalasia - complications
Esophageal diseases
Esophageal Neoplasms - etiology
Female
Follow-Up Studies
Gastroenterology
Gastrointestinal agents
Health aspects
Hepatology
Hernia
Histamine H2 Antagonists
Humans
Male
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Middle Aged
Oncology
Original Article
Pneumoviridae
Proton Pump Inhibitors
Transplant Surgery
Treatment Outcome
title Barrett’s Esophagus and Esophageal Adenocarcinoma Are Common After Treatment for Achalasia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A22%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Barrett%E2%80%99s%20Esophagus%20and%20Esophageal%20Adenocarcinoma%20Are%20Common%20After%20Treatment%20for%20Achalasia&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Leeuwenburgh,%20I.&rft.date=2013&rft.volume=58&rft.issue=1&rft.spage=244&rft.epage=252&rft.pages=244-252&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1007/s10620-012-2157-9&rft_dat=%3Cgale_proqu%3EA712946901%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c472t-eccd0309c675c4b6613440d82e965fbbb7771cc85fde758e5650422142eb01e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1282230496&rft_id=info:pmid/23179142&rft_galeid=A712946901&rfr_iscdi=true